SERUM IRON, FERRITIN AND TRANSFERIUN IN PATIENTS WITH ISCHEMIC HEART DISEASE
|Full paper||Not Available|
To shed more Light on the relationship between ischemic heart disease and iron, serum iron parameters (iron. ferritin and transferrin) were estimated in fifty ischemic heart patients (15 stable angina, 15 crescendo angina and 20 acute Myocardial Infarction, MI). Their ages ranged 43 - 58 years. Ten healthy subjects, matched with patients for age and sat served as control group. Echocardiographic studies (ejection fraction (EF) and end systolic volume (ESV) together with peak serum creatine phosphokinase (CPK) were done for each case of infarction to correints, these variables with the corresponding serum iron parameters. Compared to controls, ischemic heart patients had highly significan: increase of serum iron (103.5 + 25.6 vs 79.6 + 19.2, p<0.01) and serum ferritin (94.7± 54.2 vs 44.4± 11.0, p<0.01) whereas they showed insignificant increase of serum transferrin (273.8 + 83.8 vs 244.1 + 56.4. p>0.05). Subgroup analysis showed that there was statistically significant increase in serum iron and ferritin but not transferrin in patients with stable and unstable angina while in cases with acute Ml. there was signcant increase in all serum iron parameters. Correlation studies showed that serum iron and ferritin but not transferrin were strongly correlated with peak CPK EF and ESV. Patients with acute MI who hnti complicated in-hospital course showed significant higher value of serum iron. ferritin, transferrin, CPK and ESV but they had a significant lower EF than non-complicated cases. In conclusion, serum iron and fen-WTI were sigrufficantly higher in ischemia heart patients while serum transferrin was significantly higher only in patients with acute ML In the infarction group, the higher the serum iron and ferritin, the larger is the size of infarction, the worser is the in-hospital course and the more Unpaired is the systolic function_ Thus, the present study might give a new meaning for the emerging role of iron in ischemic heart disease.